Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of ELA026 in participants with secondary hemophagocytic lymphohistiocytosis
2025-520624-25-00Phase 3Authorised
- Sponsor
- Electra Therapeutics
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, open-label trial of ELA026 in haemophagocytic lymphohistiocytosis (HLH) (3 arms), sponsored by Electra Therapeutics. Primary endpoint: 56-day survival from time of diagnosis. Planned start Sep 2025; status: authorised.
02
Drugs
ELA026
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2025-520624-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520624-25-00.